[go: up one dir, main page]

CO2017011754A2 - Amidas heterocíclicas como inhibidores de quinasa - Google Patents

Amidas heterocíclicas como inhibidores de quinasa

Info

Publication number
CO2017011754A2
CO2017011754A2 CONC2017/0011754A CO2017011754A CO2017011754A2 CO 2017011754 A2 CO2017011754 A2 CO 2017011754A2 CO 2017011754 A CO2017011754 A CO 2017011754A CO 2017011754 A2 CO2017011754 A2 CO 2017011754A2
Authority
CO
Colombia
Prior art keywords
kinase inhibitors
heterocyclic amides
amides
heterocyclic
kinase
Prior art date
Application number
CONC2017/0011754A
Other languages
English (en)
Inventor
Niall Andrew Anderson
Deepak Bandyopadhyay
Alain Claude-Marie Daugan
Frederic G Donche
Patrick M Eidam
Nicolas Eric Faucher
Nicolas S George
Philip Anthony Harris
Jae U Jeong
Bryan W King
Clark A Sehon
Gemma Victoria White
David Duff Wisnoski
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of CO2017011754A2 publication Critical patent/CO2017011754A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se describen compuestos que tienen la fórmula: en donde R1, R2, y R3 son como se definen en este documento, y métodos de fabricación y uso de los mismos.
CONC2017/0011754A 2015-05-19 2017-11-17 Amidas heterocíclicas como inhibidores de quinasa CO2017011754A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562163552P 2015-05-19 2015-05-19
US201562167359P 2015-05-28 2015-05-28
US201562197602P 2015-07-28 2015-07-28
PCT/IB2016/052948 WO2016185423A1 (en) 2015-05-19 2016-05-19 Heterocyclic amides as kinase inhibitors

Publications (1)

Publication Number Publication Date
CO2017011754A2 true CO2017011754A2 (es) 2018-02-09

Family

ID=56080431

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0011754A CO2017011754A2 (es) 2015-05-19 2017-11-17 Amidas heterocíclicas como inhibidores de quinasa

Country Status (36)

Country Link
US (4) US10590085B2 (es)
EP (1) EP3298002B1 (es)
JP (3) JP6700311B2 (es)
KR (1) KR20180004733A (es)
CN (2) CN112370452A (es)
AU (2) AU2016263156B2 (es)
CA (1) CA2986102C (es)
CL (1) CL2017002908A1 (es)
CO (1) CO2017011754A2 (es)
CR (1) CR20170524A (es)
CY (1) CY1124187T1 (es)
DK (1) DK3298002T3 (es)
DO (1) DOP2017000267A (es)
EA (1) EA036452B1 (es)
ES (1) ES2848398T3 (es)
HK (1) HK1245244A1 (es)
HR (1) HRP20210300T1 (es)
HU (1) HUE053564T2 (es)
IL (1) IL255246A0 (es)
LT (1) LT3298002T (es)
MA (1) MA42109B1 (es)
MX (1) MX2017014809A (es)
MY (1) MY192059A (es)
NZ (1) NZ736665A (es)
PE (1) PE20180508A1 (es)
PH (1) PH12017502090A1 (es)
PL (1) PL3298002T3 (es)
PT (1) PT3298002T (es)
RS (1) RS61568B1 (es)
SG (1) SG11201708707UA (es)
SI (1) SI3298002T1 (es)
SM (1) SMT202100101T1 (es)
TW (1) TWI730959B (es)
UY (1) UY36680A (es)
WO (1) WO2016185423A1 (es)
ZA (1) ZA201707176B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
DK2502911T3 (en) 2004-06-24 2017-06-06 Vertex Pharma Modulators of ATP-binding cassette transporters
SI2404919T1 (sl) 2005-11-08 2013-12-31 Vertex Pharmaceuticals Incorporated Heterocikliäśna spojina uporabna kot modulator za prenaĺ alce z atp-vezavno kaseto
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
JP5497633B2 (ja) 2007-05-09 2014-05-21 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒのモジュレーター
ES2993060T3 (en) 2007-12-07 2024-12-20 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
PT2231606E (pt) 2007-12-07 2013-05-17 Vertex Pharma Processos para a produção de ácidos cicloalquilcarboxiamido-piridina benzóicos
CA2716109C (en) 2008-02-28 2016-07-19 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
RU2543714C2 (ru) 2009-03-20 2015-03-10 Вертекс Фармасьютикалз Инкорпорейтед Способ получения модуляторов регулятора трансмембранной проводимости кистозного фиброза
HUE056525T2 (hu) 2010-04-07 2022-02-28 Vertex Pharma 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)ciklopropánkarboxamido)-3-metilpiridin-2-il)benzoesav gyógyszerészeti készítményei és azok adagolása
BR112014021090B1 (pt) 2012-02-27 2023-01-24 Vertex Pharmaceuticals Incorporated Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma
SI3068392T1 (sl) 2013-11-12 2021-07-30 Vertex Pharmaceuticals Incorporated Postopek za pripravo farmacevtskih sestavkov za zdravljenje bolezni, ki jih posreduje CFTR
ES2882656T3 (es) 2014-11-18 2021-12-02 Vertex Pharma Proceso para realizar pruebas de alto rendimiento de cromatografía líquida de alta resolución
JP6683712B2 (ja) 2014-12-24 2020-04-22 ナショナル・インスティチュート・オブ・バイオロジカル・サイエンシズ，ベイジン ネクローシス阻害薬
UY36680A (es) 2015-05-19 2016-12-30 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas como inhibidores de quinasa
TW201831464A (zh) * 2016-11-18 2018-09-01 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
BR112019017738A2 (pt) 2017-02-27 2020-04-07 Glaxosmithkline Ip Dev Ltd combinação, composição farmacêutica, uso de uma combinação ou composição farmacêutica, método para tratar câncer em um humano, e, composto
AU2018269743B2 (en) 2017-05-17 2024-01-11 Denali Therapeutics Inc. Kinase inhibitors and uses thereof
WO2019224773A1 (en) * 2018-05-23 2019-11-28 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors
WO2019224774A1 (en) * 2018-05-23 2019-11-28 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors
WO2020044206A1 (en) 2018-08-29 2020-03-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors for use in the treatment cancer
TW202043229A (zh) 2019-01-11 2020-12-01 瑞士商赫孚孟拉羅股份公司 雙環酮化合物及其使用方法
CN109912574A (zh) * 2019-05-06 2019-06-21 合肥工业大学 一种二氢吡唑类化合物及其制备方法和用途
KR20220018483A (ko) * 2019-05-09 2022-02-15 젠플리트 테라퓨틱스 (상하이) 아이엔씨. 비스헤테로사이클릭 카보닐 치환된 디하이드로피라졸 화합물, 이의 제조방법 및 이의 약학적 용도
WO2021046515A1 (en) 2019-09-06 2021-03-11 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
IL291665B1 (en) 2019-09-27 2025-03-01 Univ Texas Inhibitors of receptor interaction with protein kinase I for the treatment of disease
CA3162605A1 (en) 2019-11-26 2021-06-03 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
EP4153570A4 (en) * 2020-05-20 2023-10-18 Sironax Ltd. AZETIDINE CYCLIC UREAS
JP2023526840A (ja) * 2020-05-20 2023-06-23 シロナックス リミテッド． ピペラジン複素環アミド尿素類を含む受容体共役タンパク質１阻害剤
IL298188A (en) 2020-05-20 2023-01-01 Sironax Ltd Piperazine cyclic ureas
TW202214617A (zh) 2020-06-02 2022-04-16 法商賽諾菲公司 作為ｒｉｐｋ１抑制劑之異㗁唑啶及其用途
CN117355506A (zh) * 2021-05-20 2024-01-05 维泰瑞隆有限公司 包括氮杂环丁烷环脲的rip1调节剂、其制备和用途
KR20240135076A (ko) 2021-08-10 2024-09-10 애브비 인코포레이티드 니코틴아미드 ripk1 억제제
EP4430037A1 (en) 2021-11-11 2024-09-18 Genzyme Corporation Isoxazolidines as ripk1 inhibitors and use thereof
TWI827429B (zh) * 2022-01-04 2023-12-21 大陸商北京賽特明強醫藥科技有限公司 羰基橋連雜環類化合物、及其組合物與應用
US11816144B2 (en) * 2022-03-31 2023-11-14 Pinterest, Inc. Hair pattern determination and filtering
CN115326999B (zh) * 2022-10-12 2022-12-27 深圳市海滨制药有限公司 一种奥司他韦环氧中间体及其异构体的检测方法
WO2024233547A1 (en) 2023-05-10 2024-11-14 Genzyme Corporation Isoxazolidines as ripk1 inhibitors and use thereof
WO2024233544A1 (en) 2023-05-10 2024-11-14 Genzyme Corporation Isoxazolidines as ripk1 inhibitors and use thereof
WO2024233554A1 (en) 2023-05-10 2024-11-14 Genzyme Corporation Isoxazolidines as ripk1 inhibitors and use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH062742B2 (ja) 1987-06-17 1994-01-12 三井東圧化学株式会社 新規２‐ピラゾリン類及びそれを有効成分とする脳血管障害治療剤
HU199825B (en) 1987-06-17 1990-03-28 Mitsui Toatsu Chemicals Process for production of new derivatives of pirasoline and medical compositions containing them
US4895947A (en) 1987-12-17 1990-01-23 Mitsui Toatsu Chemicals, Inc. Process for producing 1-acyl-2-pyrazoline derivative
CL2004000366A1 (es) 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
JP4629037B2 (ja) 2003-05-02 2011-02-09 エラン ファーマシューティカルズ，インコーポレイテッド 炎症疾患治療のためのブラジキニンｂ１受容体アンタゴニストとしての４−ブロモ−５−（２−クロロ−ベンゾイルアミノ）−１ｈ−ピラゾール−３−カルボン酸（１−（アミノカルボニル）エト−１−イル）アミド誘導体および関連化合物
AR052660A1 (es) 2005-01-21 2007-03-28 Astex Therapeutics Ltd Derivados de pirazol para inhibir la cdk's y gsk's
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester PROCESS FOR EXTENDING THE LIFE OF EUKARYOTIC ORGANISMS
EP3000468A1 (en) 2008-12-23 2016-03-30 President and Fellows of Harvard College Small molecule inhibitors of necroptosis
EP3061751A1 (en) 2010-09-21 2016-08-31 Eisai R&D Management Co., Ltd. Pharmaceutical composition
WO2012125544A2 (en) * 2011-03-11 2012-09-20 President And Fellows Of Harvard College Necroptosis inhibitors and methods of use therefor
TWI547494B (zh) * 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
TWI638815B (zh) * 2013-02-15 2018-10-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類（一）
JP6683712B2 (ja) * 2014-12-24 2020-04-22 ナショナル・インスティチュート・オブ・バイオロジカル・サイエンシズ，ベイジン ネクローシス阻害薬
UY36680A (es) 2015-05-19 2016-12-30 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas como inhibidores de quinasa
US10709692B2 (en) 2015-12-04 2020-07-14 Denali Therapeutics Inc. Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)
TW201831464A (zh) 2016-11-18 2018-09-01 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
BR112019017738A2 (pt) 2017-02-27 2020-04-07 Glaxosmithkline Ip Dev Ltd combinação, composição farmacêutica, uso de uma combinação ou composição farmacêutica, método para tratar câncer em um humano, e, composto

Also Published As

Publication number Publication date
US20210253532A1 (en) 2021-08-19
TW201718508A (zh) 2017-06-01
PH12017502090A1 (en) 2018-05-07
RS61568B1 (sr) 2021-04-29
TWI730959B (zh) 2021-06-21
EP3298002B1 (en) 2020-12-16
AU2016263156A1 (en) 2017-11-16
HUE053564T2 (hu) 2021-07-28
MA42109B1 (fr) 2021-03-31
DOP2017000267A (es) 2018-01-31
ES2848398T3 (es) 2021-08-09
DK3298002T3 (da) 2021-02-15
US11485710B2 (en) 2022-11-01
JP6893271B2 (ja) 2021-06-23
IL255246A0 (en) 2017-12-31
CL2017002908A1 (es) 2018-04-20
HRP20210300T1 (hr) 2021-04-02
AU2019201480B2 (en) 2020-06-11
SG11201708707UA (en) 2017-12-28
BR112017024941A2 (pt) 2018-07-31
CN107624111A (zh) 2018-01-23
JP2020143079A (ja) 2020-09-10
WO2016185423A1 (en) 2016-11-24
US10590085B2 (en) 2020-03-17
CA2986102C (en) 2024-01-02
US20200165205A1 (en) 2020-05-28
CR20170524A (es) 2018-01-22
SI3298002T1 (sl) 2021-04-30
LT3298002T (lt) 2021-01-11
KR20180004733A (ko) 2018-01-12
JP7204821B2 (ja) 2023-01-16
AU2019201480A1 (en) 2019-03-28
JP2021138731A (ja) 2021-09-16
JP2018515555A (ja) 2018-06-14
PE20180508A1 (es) 2018-03-09
AU2016263156B2 (en) 2018-12-06
MA42109A (fr) 2018-03-28
CN112370452A (zh) 2021-02-19
UY36680A (es) 2016-12-30
JP6700311B2 (ja) 2020-05-27
NZ736665A (en) 2024-10-25
US20180134665A1 (en) 2018-05-17
CN107624111B (zh) 2020-11-03
EP3298002A1 (en) 2018-03-28
PT3298002T (pt) 2020-12-28
ZA201707176B (en) 2019-05-29
US10899716B2 (en) 2021-01-26
EA036452B1 (ru) 2020-11-12
CA2986102A1 (en) 2016-11-24
US20230120185A1 (en) 2023-04-20
MY192059A (en) 2022-07-25
HK1245244A1 (zh) 2018-08-24
SMT202100101T1 (it) 2021-03-15
AU2019201480C1 (en) 2021-11-25
CY1124187T1 (el) 2022-05-27
PL3298002T3 (pl) 2021-06-14
EA201792535A1 (ru) 2018-10-31
MX2017014809A (es) 2018-02-09

Similar Documents

Publication Publication Date Title
CO2017011754A2 (es) Amidas heterocíclicas como inhibidores de quinasa
DOP2018000088A (es) Amidas heterocíclicas como inhibidores de cinasas
UY37487A (es) Amidas heterocíclicas como inhibidores de quinasa
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
NI201500119A (es) Compuestos de heteroarilo y sus usos
MX374558B (es) Compuestos de heteroarilo y sus usos.
ECSP15043696A (es) Compuestos de heteroarilo y sus usos
CO2019009373A2 (es) Compuestos heterocíclicos útiles como inhibidores duales de atx/ca.
EA201891211A1 (ru) Ингибиторы cxcr2
MX373247B (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina.
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
TN2017000544A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
DOP2015000059A (es) Amino-quinolinas como inhibidores de cinasa
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
EA201691412A1 (ru) Гидроксиформамидные производные и их применение
MX2015013365A (es) Derivados de urea y su uso como inhibidores de proteina de union de acidos grasos (puag).
MX2015013374A (es) Derivados de urea y su uso como inhibidores de proteina de uniuon a acidos grasos (puag).
ECSP15050110A (es) Derivados de triazina
MX373441B (es) Derivados de indol-urea glucopiranosil-sustituido y su uso como inhibidores sglt.
CR20160539A (es) Compuestos de 2-cloro-2difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos